Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 692 results for innovative

  1. Our role in the Innovative Licensing and Access Pathway (ILAP)

    The Innovative Licensing and Access Pathway (ILAP) aims to streamline patient access to safe, financially sustainable and innovative medicines.

  2. Spotlight on innovative medicines for childhood conditions

    NICE's impact on innovative medicines for childhood conditions

  3. Innovative treatment of leakage and anastomotic insufficiency

    Register an interest in this interventional procedure   ...

  4. Medical technologies guidance

    Our medical technologies guidance evaluates new, innovative medical devices and diagnostics.

  5. NICE encourages further research into the use of innovative technologies for the management of severe acute respiratory failure, and may review this guidance on publication of further evidence.

    IPG391/1 Question NICE encourages further research into the use of innovative technologies for the management of severe acute...

  6. Office for Digital Health

    The Office for Digital Health strives to accelerate NICE's efforts to deliver innovation to the health and care system.

  7. Health Technology Assessment Innovation Laboratory (HTA Lab)

    NICE's HTA Lab enables us to develop creative solutions to complex problems in health technology assessment.

  8. Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma in adults who have not had ipilimumab.

  9. Tools for building or evaluating an evidence base

    Tools for building or evaluating a medtech evidence base with NICE

  10. Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion (TA409)

    Evidence-based recommendations on aflibercept (Eylea) for treating visual impairment caused by macular oedema after branch retinal vein occlusion.

  11. Life sciences: how to get your product to market

    Support for industry to engage with NICE during all stages of health technology development

  12. Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA377)

    Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic, hormone-relapsed prostate cancer for people in whom chemotherapy is not yet clinically indicated.

  13. Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer (TA347)

    Evidence-based recommendations on nintedanib (Vargatef) for treating locally advanced, metastatic or locally recurrent non-small-cell lung cancer in adults.

  14. Register your organisation as a stakeholder

    Register your organisation as a stakeholder with NICE.

  15. Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma (TA268)

    Evidence-based recommendations on ipilimumab (Yervoy) for previously treated advanced melanoma in adults.